Ozempic vs Foundayo: Old Injection, New Pill
Ozempic (semaglutide, Novo Nordisk) vs Foundayo (orforglipron, Eli Lilly)
Last verified November 2026
The verdict
The two differ in label and in era. Ozempic is a diabetes drug with a completed cardiovascular result (MACE −26%, SUSTAIN-6) and a $349–$499 NovoCare self-pay price. Foundayo is approved for weight management, reported −11.1% at 72 weeks in ATTAIN-1, and has no cardiovascular data yet. Comparing Ozempic's −6.5 kg from SUSTAIN-7 against Foundayo's percentage is comparing a diabetes trial to an obesity trial, which is weaker evidence than the two numbers side by side suggest.
Side-by-side comparison
| Field | Ozempic | Foundayo |
|---|---|---|
| Route & frequency | Subcutaneous injection, once weekly | Oral tablet, once daily (any time, with or without food) |
| Mechanism | Peptide GLP-1 receptor agonist | Non-peptide small-molecule GLP-1 receptor agonist |
| FDA-approved indication | Type 2 diabetes; CV risk reduction in T2D + established CVD | Chronic weight management (2025); T2D pending (ACHIEVE-1 filed) |
| A1C reduction (T2D) | -1.5% / 40 wk (SUSTAIN-7, 1 mg vs dulaglutide) | About -1.5 points / 40 wk at the top dose (ACHIEVE-1; -1.24 to -1.48 across doses) |
| Weight loss (pivotal trial) | -6.5 kg / 40 wk (SUSTAIN-7, 1 mg, T2D) | -11.1% body weight / 72 wk (ATTAIN-1, 17.2 mg, obesity; Foundayo label) |
| Whether a trial proved it prevents heart attacks and strokes | SUSTAIN-6 cut major cardiac events 26% | None. No outcomes trial has reported |
| What it costs if you pay cash | $349–$499/mo via NovoCare self-pay ($499 at 2 mg) | $149–$349/mo via LillyDirect, by dose |
| The complaint people report most | Nausea, around 20% at the 1 mg dose | Nausea, 26% to 35% and rising with dose (Foundayo label) |
What each one costs in the compounded market
Standing monthly cash prices from the 734 sellers on this register. These are compounded preparations, not the approved products compared above.
Ozempic — semaglutide
from $47 /mo
463 sellers publish a standing price. This is the lowest of all 463; the median is $174 a month.
Where to get semaglutide — a selection of sellers, not a price ranking
- Embody review$79/mo
- SnagRx review$99/mo
- Collective review$59/mo + membership
Foundayo — orforglipron
from $269 /mo
1 sellers publish a standing price. This is the lowest of all 1; the median is $269 a month.
Where to get orforglipron — a selection of sellers, not a price ranking
- Bayan Health review$269/mo
⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.
Frequently asked questions
Which works better for weight loss, Ozempic or Foundayo?
Ozempic recorded -6.5 kg / 40 wk (SUSTAIN-7, 1 mg, T2D); Foundayo recorded -11.1% body weight / 72 wk (ATTAIN-1, 17.2 mg, obesity; Foundayo label). These come from separate trials with different protocols and populations, so the gap between two numbers from two studies is weaker evidence than it looks. No head-to-head trial of this pair is on record here.
Are Ozempic and Foundayo the same drug?
No. Ozempic is semaglutide and Foundayo is orforglipron — different molecules, and they work differently: Peptide GLP-1 receptor agonist against Non-peptide small-molecule GLP-1 receptor agonist. Results with one do not predict results with the other.
Is Ozempic or Foundayo cheaper?
On the manufacturers' own cash pricing: Ozempic at $349–$499/mo via NovoCare self-pay ($499 at 2 mg), Foundayo at $149–$349/mo via LillyDirect, by dose. That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.
What does a compounded version of each actually cost?
Across the 734 sellers in this register, the cheapest standing monthly cash prices we hold are semaglutide from $47 a month and orforglipron from $269 a month. A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.
Can I switch from Ozempic to Foundayo?
Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.
Which one should I ask for?
That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.
References
- 1.Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025. PMID: 40960239.
- 2.Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1). N Engl J Med. 2025. PMID: 40544435.
- 3.Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (Phase 2). N Engl J Med. 2023. PMID: 37351564.
- 4.Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016. PMID: 27633186.
- 5.Pratley RE, Aroda VR, Lingvay I, Ludemann J, Andreassen C, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018. PMID: 29397376.
- 6.Novo Nordisk Pharmaceutical Industries, LP. OZEMPIC (semaglutide) injection prescribing information. DailyMed (FDA label). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- 7.Eli Lilly and Company. Lilly's Foundayo (orforglipron) approved by U.S. FDA for chronic weight management. Lilly Press Release. 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-approved-us-fda-chronic-weight
- 8.Eli Lilly and Company Foundayo (orforglipron) tablets, prescribing information DailyMed (NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
Related comparisons
- Wegovy vs Ozempic
- Wegovy vs Foundayo
- Ozempic vs Trulicity
- Foundayo vs Mounjaro
- Saxenda vs Foundayo
- Saxenda vs Ozempic
See the full drug-vs-drug verdict index or provider rankings.